Sam E. Gary
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sam E. Gary has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Abbey Rocco
Division of Pediatric Hematology and Oncology, Department of Pediatrics, The University of Alabama at Birmingham, Birmingham, Alabama. 1
28 shared publications - Elizabeth A. Beierle
Division of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA
28 shared publications - Gregory K. Friedman
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, USA
28 shared publications - James M. Markert
Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA
28 shared publications - Joshua D. Bernstock
Department of Neurosurgery, Brigham and Women’s Hospital, Mass General Brigham, Boston, Massachusetts
28 shared publications - Kyung-Don Kang
Department of Pediatrics, The University of Alabama at Birmingham, Birmingham, Alabama. 7
28 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Neurological Medicine
- Vol. 2026 (1) , 8933434
Presentation of Neurological Rosai–Dorfman Disease Over 12 Years: A Case Report
Rosai–Dorfman disease (RDD) is a rare, non‐Langerhans cell histiocytosis that classically presents with cervical lymphadenopathy. Neurological involvement occurs in less than 5% of cases and is often associated with extra‐axial lesions. Diagnosis of RDD in the setting of neurological deficits is challenging, as RDD often mimics meningioma and neurosarcoidosis on neuroimaging. Herein, we describe a case report of a 50‐year‐old African American man who was previously treated with radiation for presumed meningioma of the brainstem 12 years prior to the current presentation. The brainstem lesion progressed to include the pachymeninges despite radiation, and the patient developed papilledema and involvement of the bilateral cochlea. Lack of response to radiation, involvement of the pachymeninges, and development of papilledema and bilateral hearing loss led to an updated diagnosis of neurosarcoidosis. On current presentation, the patient was brought to the emergency department for altered mental status, seizures, and left‐sided hemiparesis. Initial workup was negative for stroke, meningitis, and toxic or metabolic encephalopathies. Long‐term electroencephalography confirmed seizures originating from the right frontal lobe, which was controlled with antiseizure medications. Magnetic resonance imaging revealed worsening diffuse brainstem and pachymeningeal enhancement of the bilateral cerebral convexities, suggesting progression of the disease. Workup for systemic malignancy revealed a hypodense soft tissue mass encasing the left kidney, raising concern for metastatic disease. Biopsy of the meninges and the renal mass confirmed RDD with multiorgan involvement. Diagnosis of RDD in this patient marks the longest duration from onset to diagnosis ever reported, indicating the need for tissue diagnostics in uncertain cases.
- 1 January 2026
- Published by Wiley in Case Reports in Neurological Medicine
- Vol. 2026 (1) , 8933434
Open AccessPresentation of Neurological Rosai–Dorfman Disease Over 12 Years: A Case Report
Rosai–Dorfman disease (RDD) is a rare, non‐Langerhans cell histiocytosis that classically presents with cervical lymphadenopathy. Neurological involvement occurs in less than 5% of cases and is often associated with extra‐axial lesions. Diagnosis of RDD in the setting of neurological deficits is challenging, as RDD often mimics meningioma and neurosarcoidosis on neuroimaging. Herein, we describe a case report of a 50‐year‐old African American man who was previously treated with radiation for presumed meningioma of the brainstem 12 years prior to the current presentation. The brainstem lesion progressed to include the pachymeninges despite radiation, and the patient developed papilledema and involvement of the bilateral cochlea. Lack of response to radiation, involvement of the pachymeninges, and development of papilledema and bilateral hearing loss led to an updated diagnosis of neurosarcoidosis. On current presentation, the patient was brought to the emergency department for altered mental status, seizures, and left‐sided hemiparesis. Initial workup was negative for stroke, meningitis, and toxic or metabolic encephalopathies. Long‐term electroencephalography confirmed seizures originating from the right frontal lobe, which was controlled with antiseizure medications. Magnetic resonance imaging revealed worsening diffuse brainstem and pachymeningeal enhancement of the bilateral cerebral convexities, suggesting progression of the disease. Workup for systemic malignancy revealed a hypodense soft tissue mass encasing the left kidney, raising concern for metastatic disease. Biopsy of the meninges and the renal mass confirmed RDD with multiorgan involvement. Diagnosis of RDD in this patient marks the longest duration from onset to diagnosis ever reported, indicating the need for tissue diagnostics in uncertain cases.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Toxicity from IVT oHSV in the left lateral ventricle and third and fourth ventricles at different time points.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Toxicity from IVT oHSV in the left lateral ventricle and third and fourth ventricles at different time points.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Interferon β (IFN β) levels over time in the CSF after a single 50 µg IVT dose of poly I:C or saline (N = 2 mice/group/time point).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Interferon β (IFN β) levels over time in the CSF after a single 50 µg IVT dose of poly I:C or saline (N = 2 mice/group/time point).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Toxicity with repeated doses of IVT oHSV.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Toxicity with repeated doses of IVT oHSV.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Body weights of CBA/J, BALB/c and C57BL/6 mice (N = 5/group) after inoculation with 1x107 PFU of IVT oHSV.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Body weights of CBA/J, BALB/c and C57BL/6 mice (N = 5/group) after inoculation with 1x107 PFU of IVT oHSV.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Comparison of the protective effect of different pretreatment low doses of IVT oHSV from toxicity after a subsequent treatment dose.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Comparison of the protective effect of different pretreatment low doses of IVT oHSV from toxicity after a subsequent treatment dose.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Time to recover baseline body weight in mice pretreated with low-dose oHSV prior to a standard treatment dose.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Time to recover baseline body weight in mice pretreated with low-dose oHSV prior to a standard treatment dose.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
IHC staining of the ependymal lining for CD8+ cells and confirmation of CD8 depletion.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
IHC staining of the ependymal lining for CD8+ cells and confirmation of CD8 depletion.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Effects of poly I:C alone and combined with oHSV in vitro and in vivo.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Effects of poly I:C alone and combined with oHSV in vitro and in vivo.
- Open Access
Temozolomide and the PARP Inhibitor Niraparib Enhance Expression of Natural Killer Group 2D Ligand ULBP1 and Gamma-Delta T Cell Cytotoxicity in Glioblastoma
Glioblastoma (GBM) is an immunologically cold tumor, but several immunotherapy-based strategies show promise, including the administration of ex vivo expanded and activated cytotoxic gamma delta T cells. Cytotoxicity is partially mediated through interactions with natural killer group 2D ligands (NKG2DL) on tumor cells. We sought to determine whether the addition of the blood–brain barrier penetrant PARP inhibitor niraparib to the standard of care DNA alkylator temozolomide (TMZ) could upregulate NKG2DL, thereby improving immune cell recognition. Changes in viability were consistent with prior publications as there was a growth inhibitory effect of the combination of TMZ and niraparib. However, decreases in viability did not always correlate with changes in NKG2DL mRNA. ULBP1/Mult-1 mRNA was increased with the combination therapy in comparison to either drug alone in two of the three cell types tested, even though viability was consistently decreased. mRNA expression correlated with protein levels and ULBP1/MULT-1 cell surface protein was significantly increased with TMZ and niraparib treatment in four of the five cell types tested. Gamma delta T cell-mediated cytotoxicity at a 10:1 effector-to-target ratio was significantly increased upon pretreatment of cells derived from a GBM PDX with TMZ and niraparib in comparison to the control or either drug alone. Together, these data demonstrate that the combination of PARP inhibition, DNA alkylation, and gamma delta T cell therapy has the potential for the treatment of GBM.
Open AccessTemozolomide and the PARP Inhibitor Niraparib Enhance Expression of Natural Killer Group 2D Ligand ULBP1 and Gamma-Delta T Cell Cytotoxicity in Glioblastoma
Glioblastoma (GBM) is an immunologically cold tumor, but several immunotherapy-based strategies show promise, including the administration of ex vivo expanded and activated cytotoxic gamma delta T cells. Cytotoxicity is partially mediated through interactions with natural killer group 2D ligands (NKG2DL) on tumor cells. We sought to determine whether the addition of the blood–brain barrier penetrant PARP inhibitor niraparib to the standard of care DNA alkylator temozolomide (TMZ) could upregulate NKG2DL, thereby improving immune cell recognition. Changes in viability were consistent with prior publications as there was a growth inhibitory effect of the combination of TMZ and niraparib. However, decreases in viability did not always correlate with changes in NKG2DL mRNA. ULBP1/Mult-1 mRNA was increased with the combination therapy in comparison to either drug alone in two of the three cell types tested, even though viability was consistently decreased. mRNA expression correlated with protein levels and ULBP1/MULT-1 cell surface protein was significantly increased with TMZ and niraparib treatment in four of the five cell types tested. Gamma delta T cell-mediated cytotoxicity at a 10:1 effector-to-target ratio was significantly increased upon pretreatment of cells derived from a GBM PDX with TMZ and niraparib in comparison to the control or either drug alone. Together, these data demonstrate that the combination of PARP inhibition, DNA alkylation, and gamma delta T cell therapy has the potential for the treatment of GBM.